1 COVID-19 AND KIDNEY INJURY

The ongoing SARS-Coronavirus-2 pandemic leading to widespread Coronavirus-2019 disease (COVID-19) brings into the focus the paramount need for disaster planning within the nephrology community.1 While the dramatic burden of respiratory failure and need for mechanical ventilation among patients with SARS-CoV-2 infection were recognized early in the pandemic and led to appropriate disaster planning, the recognition of the high rates of acute kidney injury (AKI) and subsequent need for renal replacement therapies (RRTs) in COVID-19 were delayed.1

Early reports out of China appeared to have incomplete reporting of AKI with incidences as low as 0.5%–3%.2, 3 Later reports including some from ICU cohorts reported wider variations in the incidence of AKI 5%–23%, but direct comparisons were limited by the absence of granular reporting on clinical information to compare the underlying severity of these cohorts.4-7 One large cohort in New York City (the hotspot early in the pandemic) reported an overall AKI incidence of 47%, with 31% stage 3 severity.8 Similarly, a single-center report from New Orleans, another city heavily affected during the early days of the pandemic, reported 28% incidence of AKI with 55% requirement of RRT and 50% in-hospital mortality.9 Differences in admission criteria and frequent absence of preadmission measures of kidney function limited the ability to draw precise conclusions on the burden of severe kidney disease.8 A detailed systematic review and meta-analysis estimated the incidence of AKI among hospitalized patients to be as high as 17%.10 The predominant mechanism of renal injury appears to be acute tubular necrosis, as evidenced by pathological evaluation of urinary sediment microscopy,11 kidney biopsies,12, 13 and autopsies14, 15 of patients with COVID-19 and AKI. Collapsing glomerulopathy (COVID-19-associated nephropathy, COVAN) and other podocytopathies have also been reported in individuals with African and other ancestry.16-18 Whether there is a direct impact of SARS-CoV2 infection on the kidney remains uncertain with some investigators reporting on the identification of the viral particles on electron microscopy.19

2 SURGE IN RRT NEEDS

In the most severe disease, usually characterized by circulatory shock and ARDS requiring mechanical ventilation, severe AKI requiring RRT is quite common. It is now estimated that nearly 5% of hospitalized patients require some form of RRT for AKI,10 while 20%–31% of critically ill patients develop indications for RRT.10, 20, 21 Not surprisingly, kidney injury among critically ill patients with COVID-19 is also associated with a particularly poor outcome. This dramatic increase in demand in the face of unprecedented hospitalization rates and ICU censuses to accommodate the surge of patients has presented a unique challenge to the health-care system and in particular for nephrology services, as a surge in demand of this scale has not been seen outside of crush injuries from natural disasters. The absence of early estimates of the true burden of kidney injury created a situation where RRT resource planning did not occur ahead of time. It should be noted that this increased need for RRT does not include the increase in dialysis-dependent patients with end-stage kidney disease needing hospitalization and continued maintenance RRT. Providing RRT both in the ICU and outside is a resource intense procedure that requires significant capital investments (dialysis machines), consumables (filters and blood lines), dialysate fluids (either continuous produced or in pre-packed sterile bags), and health-care workers (dialysis nurses and technicians) with appropriate advanced training. As a result, RRT is dependent on a robust supply chain that had not previously been faced with such a rapid, sustained, and widespread increase in demand. As an example, the projected shortfall in continuous renal replacement therapy (CRRT) machines across just six states in the United States with a COVID surge was nearly 1000 machines.22

3 ADAPTING TO RESOURCE SHORTAGES

At the height of the first COVID-19 surge in NYC, the number of patients with indications for RRT exceeded the availability of CRRT resources.1 Different strategies for delivering RRT to these critically ill patients needed to be explored, and factors that influenced our decisions to adopt different strategies are summarized in Table 1. Given the paucity of devices and the challenges of intermittent hemodialysis (HD) in hemodynamically unstable patients, several large academic centers shifted to protocols that allowed devices to be shared between patients resulting in the use of traditionally continuous therapies in a non-continuous manner—an approach that has previously been referred to as either prolonged intermittent renal replacement therapy (PIRRT) or accelerated veno-venous hemofiltration.23-25 While prior intermittent strategies have utilized a 12-h on and 12-h off strategy, often to facilitate early mobilization of ICU patients, this frequent change results in a dramatic increase in consumable burn rate where filters are discarded every 12 h instead of every 48–72 h. In contrast, a 24-h on/off strategy is associated with a much lower rate of filter usage, still allows for adequate clearance at similar dialysate flow rates, and similar volume management achieved of the 12-h on/12-h off strategy.1 Notably, however, this approach also allowed for a lower nursing burden by decreasing the frequency of changes for the patients, less down time for each device associated with priming/return of blood, and simplifying the logistic challenges associated with coordinating the movement of machines among an ever changing cohort of critically ill patients across a large geographical footprint of the hospital. Using novel tracking tools, such as a CRRT sharing tool, allowed for regionalization of machines and geographical patient pairings and facilitated the orchestration of efficient and accurate machine movement across the hospital and across multiple hospitals in a health-care system.26

TABLE 1. Different RRT modalities and strategies with factors that influence decisions Modality Intermittent HD 24 hours CRRT Hybrid RRT Acute PD Strategy Conventional thrice weekly hemodialysis Conventional CRRT (CVVHD, CVVH, or CVVHDF) Accelerated RRT or PIRRT (6–24 h out of 48 h) Emergent bedside PD catheter placement and rapid start PD in the ICU Personnel

HD Technicians

HD RNs

ICU RNs ICU or HD RNs (depending on institution) ICU or PD RNs (depending on institution) Pros Provides sufficient clearance in a short amount of time, allowing for more than one patient treatment in a 24-h period Limits unnecessary exposure of HD RNs when ICU RNs already entering room Maximizes the number of patients able to provide RRT during pandemics/disasters (i.e., >1 patient per machine per day) Allows for expansion of an RRT program beyond the confines of HD machines, CRRT machines, and PD cyclers (by utilizing CAPD) Cons Not recommended in hemodynamically unstable patients Unnecessary exposure of HD RNs in addition to already exposed ICU RNs Unnecessary PPE use for dedicated HD RN to also enter the room Does nothing to address the mismatch in demand vs. supply Limits the capacity of a CRRT program to one patient per machine per day and does not increase capacity during a disaster Prolonged filter exposure time may lead to increased clotting Logistic challenges sharing machines in a large CRRT program Uncertainty with medication dosing in accelerated RRT and PIRRT modalities Patients requiring proning for severe ARDS not suitable candidates Patients requiring high O2 or high positive end-expiratory pressures may not be suitable candidates Peritoneal leaks Unnecessary PD RN exposure and PPE consumption for frequency of entering the room for CAPD

While this sharing protocol strategy addresses the dearth of available CRRT resources during a surge in need, it does not address vulnerabilities in the supply chain of therapy fluid (dialysate and replacement fluid). Such a protocol allows for two patients to receive RRT with one device, ensuring that they are receiving adequate clearance averaged over 48 h, but this requires using increased flow rates to achieve adequate clearance. In other words, the amount of dialysis or replacement fluid being used per machine is doubled—while still at recommended clearance goals per patient. One approach to conserve commercially available therapy fluid that was utilized by some during the pandemic surge is a nomogram to prescribe a specific number of 5 L therapy fluid bags per patient per day rather than prescribing only in mL/min.1 During any sharing protocol, this prevents the waste of partially used therapy fluid bags at the end of the treatment session. Another strategy employed was dropping the therapy fluid dosing down to the lower limit of the recommended range (20 vs 25 mL/kg/h) in patients who were not hypercatabolic in order to prolong the lifespan of the supply.1 Finally, in order to be less reliant on a stretched supply chain, which other institutions are competing for, some centers developed protocols for on-site dialysate production for CRRT using a conventional hemodialysis machine to generate dialysate for use on CRRT.

Importantly, some institutions have access to other CRRT or PIRRT platforms that provide alternative ways to handle the increased need. In one report, sustained low efficiency dialysis (SLED) was the modality of choice.27 Because of its higher dialysis dose delivery, SLED allows for 8–10 h treatments, thus freeing a dialysis machine to be used for two patients within the same day. In addition, SLED does not require consumable dialysis solutions because it utilizes the hospital water supply. While SLED may offer some of those advantages, it also requires allocation of reverse osmosis machines for water purification as well as effective nursing. In the absence of SLED-trained ICU nurses, its implementation may be hindered by the need of a dialysis nurse at the bedside for prolonged periods of time.

Finally, at the height of the surge, some New York City hospitals turned to acute peritoneal dialysis (PD) to expand their dialytic capacity beyond the confines of CRRT and HD machines. There are important caveats to patient selection detailed in the description of their experiences utilizing low volume dwells (to avoid ventilatory compromise) and acute PD in patients with severe COVID-19 illness.28-31 Importantly, patients with high oxygen or positive expiratory end-pressures and patients requiring proning were in general not considered candidates for acute PD at our institution.

4 POTENTIAL COMPLICATIONS

There are a number of unique factors to take into consideration when reorganizing a CRRT program as we have described so far. First is the hypercoagulability seen in COVID-19 disease, and the challenges this places on a vulnerable supply of cartridges and blood products and trying to minimize nursing to patient contact time to protect nurses from occupational COVID exposure. One group described their experience using different forms of circuit anticoagulation in 80 COVID patients on CRRT, with a median filter life of only 21 h. The three strategies that resulted in the longest filter lifespans in descending order were: (a) regional citrate anticoagulation plus systemic heparin (for non-CRRT indications), (b) argatroban, and (c) systemic heparin. Utilizing pre-filter heparin strategies or no anticoagulation at all led to the shortest filter lifespans. Another group described their experience using protocolized systemic heparin dosing by following anti-factor Xa levels (targeting 0.3–0.7 IU/mL) rather than PTT.34 Compared to standard of care (i.e., adjusting by PTT), the anti-factor Xa protocol did not lead to differences in filter losses until the third filter clotting event (event rates for first two clotting events remained the same).34 SLED-based protocols were also associated with increased heparin usage.27 Our institution adopted a CRRT anticoagulation protocol, which directs clinicians to initiate pre-filter heparin as a default when no clinical contraindications exist. If filter clotting persists, the next step would be to consider starting regional citrate anticoagulation if available. If RCA not available, then move to initiate full systemic anticoagulation with unfractionated heparin while monitoring anti-Xa levels targeting 0.3–0.7 units/mL (requires availability of anti-Xa levels with rapid turnaround). If the circuit continues to clot to transition to systemic argatroban. Finally if the circuit continues to clot despite all of the above and therapeutic PTT on argatroban to consult Hematology for guidance (Figure S1). This algorithm underscores the extreme hypercoagulability in this group of patients and the unique demands that it places on CRRT resource consumption and RN workload in an already vulnerable system.32, 33

Line placement site is another additional factor that needs careful consideration. Given the spatial complexities with proning patients, internal jugular dialysis access sites are preferred over femoral or subclavian sites.35 The CRRT blood circuit is disconnected from the patient during the actual process of proning and supinating patients in order to prevent kinking and wrapping around the advanced airway. While there are anecdotal reports of using blood line extension tubing in order to allow the CRRT machine to remain outside of the ICU room to minimize nursing exposure and conserve PPE, there are no studies examining whether this leads to increased machine alarms, performance of pressure monitors, and filter clotting. It is for this theoretical concern that while our institution did use therapy fluid extension lines to allow for therapy fluid bag exchanges to occur outside of the patient room, we actively decided not to pursue blood line extenders given the high rates of clotting we were already experiencing. Of note, certain device cartridges already incorporate extended tubing to facilitate use with citrate anticoagulation, which would also lend themselves well to placing the CRRT device outside the patient rooms.

For patients receiving medications that are renally or extracorporeally cleared by RRT, hybrid therapies with shared protocols complicate medication dosing. These “accelerated” therapies provide faster clearance than traditional CRRT therapies but less than conventional HD and leaves the provider to make difficult decisions about appropriate dosing with a lack of evidence-based resources to inform their decision. While time-averaged clearance of small molecules is largely unchanged, medications that are dosed once daily or more frequently are going to be impacted by the variations in drug clearances underscoring the need for careful attention to drug dosing. Therapeutic drug monitoring should be utilized when possible, and clinical ICU pharmacists should be involved in selecting the most appropriate dosing regimen when utilizing accelerated RRT protocols. Additionally, there is a compendium of dosing strategies in the literature as a starting point for clinicians faced with this challenge.36

Finally, the discussion on role of extracorporeal cytokine clearance has been revived by the cytokine storm that is seen in critically ill patients with COVID-19. Case reports and small case series have described hemadsorption and convective clearance of cytokines in COVID-19 using CVVH, CVVHDF, and novel membrane technologies37-39; however, given the observational reporting on these strategies, it remains unclear what (if any) role these therapies have on outcomes in patients with AKI requiring CRRT in the setting of cytokine storm.

5 OUTCOMES—DEATH, KIDNEY RECOVERY, AND DIALYSIS DEPENDENCY

Among survivors, careful monitoring for renal recovery is paramount, not only during the index hospitalization but even after discharge given that survivors experience continued renal recovery. While definitions for renal recovery vary substantially, it is usually heralded by an increase in urine output, which is the best predictor of renal recovery and successful discontinuation of RRT.28, 40-42 The reported volumes of UOP that best predict recovery also vary in the literature: >0.5–1 L/day unassisted or >2 L/day with diuretics in clinical trials and ~0.4 L/day unassisted or >2.3 L/day with diuretics in observational studies. Other clinical changes that should alert providers to imminent recovery are: a spontaneous decline in SCr, a decrease in interdialytic weight gain (suggesting undocumented urine output), or an increase in calculated native renal clearance with timed urine collections.40 What, if any, impact dialysis-dependent AKI will have on the long-term prevalence of ESKD or the rates of renal recovery among patients who remain dialysis-dependent for longer duration remains to be seen.43

Prior studies have found that acute tubular injury (ATN) on biopsy is one predictor of renal recovery.44 The high rates of renal recovery now being seen in COVID-19 AKI survivors are in line with the predominant pathological finding of ATN previously described, where the authors describe a pattern of tubular injury that appears less severe than the clinical phenotype and has been described as a “recoverable” finding. Other factors affecting recovery versus dependency include both the severity and duration of the AKI episode, the length of time on RRT, baseline CKD, age, comorbid diabetes mellitus, comorbid congestive heart failure, and the number of pre-existing comorbidities.40, 43, 45

Between 27% and 64% of COVID-19 patients who required RRT were able to have RRT discontinued by 28 days or by ICU discharge.21, 46, 47 Another study reported a 42% rate of renal recovery after needing RRT; however, the length of follow-up is unclear.48 Furthermore, one study reported that among 216 patients with COVID-19 discharged from the hospital, 73 (34%) were still RRT-dependent, and among 69 of those patients who were still alive by day 60, 39 (57%) were still RRT-dependent.4 Long-term follow-up in COVID-19 AKI survivors beyond 60 days is not yet reported; however, we can learn from the experiences of prior observational studies of severe AKI requiring RRT. Among patients hospitalized with AKI requiring RRT, only 15%–30% of survivors still required RRT at discharge (70%–85% recovery in survivors),49, 50 and by 30 days after discharge, 43% of patients who were RRT-dependent at discharge had recovered renal function. The majority of post-discharge renal recovery occurs within 3 months (73% of all recovery)44 and continues to occur in the first among survivors of severe AKI in the ICU.51

6 CONCLUSIONS

Acute kidney injury is a common complication among patients hospitalized with COVID-19, especially among those with more severe infections. The need for RRTs in those with the most severe forms of AKI is considerable and risks overwhelming health-care systems at the peak of a surge. Careful planning with shared protocols and an awareness of the consumable supply are essential prerequisites for a successful RRT strategy. Taking careful inventory of all aspects of an RRT program (personnel, consumables, and machines) before a surge in RRT arises and developing disaster contingency protocols for sharing CRRT and utilizing acute PD when absolutely necessary are paramount to a successful response to such a disaster. Long-term outcomes among survivors including the extent and duration of renal recovery remain to be seen.

ACKNOWLEDGMENTS

JSS and SM are supported by the National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK126739). SM is also supported by National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK114893, R01 and U01 116066) and the National Institute of Minority Health and Health Disparities (R01 DK126739).

CONFLICT OF INTEREST

The authors declare that they have no financial conflict of interest to disclose.

Filename Description sdi12962-sup-0001-FigureS1.pdfPDF document, 274.9 KB Figure S1

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

REFERENCES

1 Division of Nephrology CUVCoP. Disaster response to the COVID-19 pandemic for patients with kidney disease in New York City. J Am Soc Nephrol. 2020; 31: 1371- 1379. 2Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395: 507- 513. 3Guan W-J, Ni Z-Y, Hu YU, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382: 1708- 1720. 4Gupta S, Coca SG, Chan L, et al. AKI treated with renal replacement therapy in critically Ill patients with COVID-19. J Am Soc Nephrol. 2020. 5Cheng Y, Luo R, Wang K, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020; 97: 829- 838. 6Arentz M, Yim E, Klaff L, et al. Characteristics and outcomes of 21 critically Ill patients with COVID-19 in Washington state. JAMA. 2020; 323: 1612- 1614. 7 ICNARC Accessed May 1. https://www.icnarc.org/Our-Audit/Audits/Cmp/Reports. 8Hirsch JS, Ng JH, Ross DW, et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int. 2020; 98: 209- 218. 9Mohamed MMB, Lukitsch I, Torres-Ortiz AE, et al. Acute kidney injury associated with coronavirus disease 2019 in urban New Orleans. Kidney360. 2020; 1: 614- 622. 10Robbins-Juarez SY, Qian L, King KL, et al. Outcomes for patients with COVID-19 and acute kidney injury: a systematic review and meta-analysis. Kidney Int Rep. 2020; 5: 1149- 1160. 11Cesar F, Hernandez-Arroyo VV, Mohamed MMB, Velez JCQ. Urinary sediment microscopy in acute kidney injury associated with COVID-19. Kidney360. 2020; 1: 819- 823. 12Kudose S, Batal I, Santoriello D, et al. Kidney biopsy findings in patients with COVID-19. J Am Soc Nephrol. 2020; 31(9): 1959- 1968. 13Sharma P, Uppal NN, Wanchoo R, et al. COVID-19–Associated kidney injury: a case series of kidney biopsy findings. J Am Soc Nephrol. 2020; 31 (9): 1948– 1958. http://dx.doi.org/10.1681/asn.2020050699 14Golmai P, Larsen CP, DeVita MV, et al. Histopathologic and ultrastructural findings in postmortem kidney biopsy material in 12 patients with AKI and COVID-19. J Am Soc Nephrol. 2020; 31(9): 1944- 1947. 15Santoriello D, Khairallah P, Bomback AS, et al. Postmortem kidney pathology findings in patients with COVID-19. J Am Soc Nephrol. 2020; 31(9): 2158- 2167. https://doi.org/10.1681/ASN.2020050744 16Velez JCQ, Caza T, Larsen CP. COVAN is the new HIVAN: the re-emergence of collapsing glomerulopathy with COVID-19. Nat Rev Nephrol 2020; 16: 565- 567. 17Shetty AA, Tawhari I, Safar-Boueri L, et al. COVID-19-associated glomerular disease. J Am Soc Nephrol. 2021; 32(1): 33- 40. 18Deshmukh S, Zhou XJ, Hiser W. Collapsing glomerulopathy in a patient of Indian descent in the setting of COVID-19. Ren Fail. 2020; 42: 877- 880. 19Farkash EA, Wilson AM, Jentzen JM. Ultrastructural evidence for direct renal infection with SARS-CoV-2. J Am Soc Nephrol. 2020; 31: 1683- 1687. 20Cummings MJ, Baldwin MR, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020; 395: 1763- 1770. 21Gupta S, Hayek SS, Wang W, et al. Factors associated with death in critically Ill patients with coronavirus disease 2019 in the US. JAMA Intern Med. 2020; 180 (11): 1436. http://dx.doi.org/10.1001/jamainternmed.2020.3596 22Reddy YNV, Walensky RP, Mendu ML, Green N, Reddy KP. Estimating shortages in capacity to deliver continuous kidney replacement therapy during the COVID-19 pandemic in the United States. Am J Kidney Dis. 2020; 76: 696- 709.e1. 23Edrees F, Li T, Vijayan A. Prolonged intermittent renal replacement therapy. Adv Chronic Kidney Dis. 2016; 23: 195- 202. 24Bellomo R, Baldwin I, Fealy N. Prolonged intermittent renal replacement therapy in the intensive care unit. Crit Care Resusc. 2002; 4: 281- 290. 25Allegretti A, Endres P, Parris T, et al. Accelerated venovenous hemofiltration as a transitional renal replacement therapy in the intensive care unit. Am J Nephrol. 2020; 51: 318- 326. 26Akomeah J, Apostol A, Barnes E, et al. Optimizing kidney replacement therapy during the COVID-19 pandemic across a complex healthcare system. Front Medi. 2020; 7. http://dx.doi.org/10.3389/fmed.2020.604182 27Wen Y, LeDoux JR, Mohamed M, et al. Dialysis filter life, anticoagulation and inflammation in COVID-19 and acute kidney injury. Kidney360. 2020; 1(12): 1426- 1431. 28 KDIGO. KDIGO clinical practice guideline for acute kidney injury. Kidney International Supplements 2012;2. 29Akomeah J, Apostol A, Barnes E, et al. Optimizing kidney replacement therapy during the covid-19 pandemic across a complex healthcare system. Front Med (Lausanne). 2020; 7: 604182. 30Shankaranarayanan D, Neupane SP, Varma E, et al. Peritoneal dialysis for acute kidney injury during the COVID-19 pandemic in New York City. Kidney Int Rep. 2020; 5: 1532- 1534. 31Shimonov D, Srivatana V. Peritoneal dialysis for acute kidney injury during the COVID-19 Pandemic. Clin J Am Soc Nephrol. 2020; 15: 1829- 1831. 32Roberts LN, Bramham K, Sharpe CC, Arya R. Hypercoagulability and anticoagulation in patients with COVID-19 requiring renal replacement therapy. Kidney Int Rep. 2020; 5: 1377- 1380. 33Shankaranarayanan D, Muthukumar T, Barbar T, et al. Anticoagulation strategies and filter life in COVID-19 patients receiving continuous renal replacement therapy: A single-center experience. Clin J Am Soc Nephrol. 2021; 16(1): 124- 126. 34Endres P, Rosovsky R, Zhao S, et al. Filter clotting with continuous renal replacement therapy in COVID-19. J Thromb Thrombolysis. 2020. http://dx.doi.org/10.1007/s11239-020-02301-6 35Nadim MK, Forni LG, Mehta RL, et al. COVID-19-associated acute kidney injury: consensus report of the 25th acute disease quality initiative (ADQI) workgroup. Nat Rev Nephrol. 2020; 16: 747- 764. 36Hoff BM, Maker JH, Dager WE, Heintz BH. Antibiotic dosing for critically ill adult patients receiving intermittent hemodialysis, prolonged intermittent renal replacement therapy, and continuous renal replacement therapy: an update. Ann Pharmacother. 2020; 54: 43- 55. 37Bonavia A, Groff A, Karamchandani K, Singbartl K. Clinical utility of extracorporeal cytokine hemoadsorption therapy: A literature review. Blood Purif. 2018; 46: 337- 349. 38Esmaeili Vardanjani A, Ronco C, Rafiei H, Golitaleb M, Pishvaei MH, Mohammadi M. Early hemoperfusion for cytokine removal may contribute to prevention of intubation in patients Infected with COVID-19. Blood Purif. 2020; 1– 4. http://dx.doi.org/10.1159/000509107 39Zhang Hongtao, Zhu Guizhen, Yan Lei, Lu Yang, Fang Qiying, Shao Fengmin. The absorbing filter Oxiris in severe coronavirus disease 2019 patients: A case series. Artificial Organs. 2020; 44 (12): 1296– 1302. http://dx.doi.org/10.1111/aor.13786 40Cerdá J, Liu KD, Cruz DN, et al. Promoting kidney function recovery in patients with AKI Requiring RRT. Clin J Am Soc Nephrol. 2015; 10: 1859- 1867. 41Hansrivijit P, Yarlagadda K, Puthenpura MM, et al. A meta-analysis of clinical predictors for renal recovery and overall mortality in acute kidney injury requiring continuous renal replacement therapy. J Crit Care. 2020; 60: 13- 22. 42Uchino S, Bellomo R, Morimatsu H, et al. Discontinuation of continuous renal replacement therapy: a post hoc analysis of a prospective multicenter observational study. Crit Care Med. 2009; 37: 2576- 2582. 43Mohan S, Huff E, Wish J, et al. Recovery of renal function among ESRD patients in the US Medicare program. PLoS One. 2013; 8:e83447. 44Hickson LJ, Chaudhary S, Williams AW, et al. Predictors of outpatient kidney function recovery among patients who initiate hemodialysis in the hospital. Am J Kidney Dis. 2015; 65: 592- 602. 45James MT, Bhatt M, Pannu N, Tonelli M. Long-term outcomes of acute kidney injury and strategies for improved care. Nat Rev Nephrol. 2020; 16: 193- 205. 46Wilbers TJ, Koning MV. Renal replacement therapy in critically ill patients with COVID-19: a retrospective study investigating mortality, renal recovery and filter lifetime. J Crit Care. 2020; 60: 103- 105. 47Stevens JS, King KL, Robbins-Juarez SY, et al. High rate of renal recovery in survivors of COVID-19 associated acute renal failure requiring renal replacement therapy. PLoS One. 2020; 15(12):e0244131. 48Fisher M, Neugarten J, Bellin E, et al. AKI in hospitalized pati